Nasus Pharma Ltd
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Non-accelerated filerEmerging growth company
State of Incorporation
Israel
Business Address
29 HARAKEVET ST, TEL AVIV - YAFO, L3, 6618003
Mailing Address
29 HARAKEVET ST, TEL AVIV - YAFO, L3, 6618003
Phone
972 54-255-3956
Fiscal Year End
1231
EIN
516022712
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 3 Initial insider ownership report | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 27, 2026 | View on SEC |
| 3 Initial insider ownership report | March 27, 2026 | View on SEC |
| 6-K Foreign company current report | March 25, 2026 | View on SEC |
Annual Reports
20-F
March 25, 2026
- Successful IPO on the NYSE American in August 2025, raising $12 million.
- Proprietary powder-based nasal spray technology offers needle-free, rapid drug absorption.
Insider Trading
BUY
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.